MOTS-c · Clinical molecule review
Clinic Terrain reviews MOTS-c molecule by molecule, identity, mechanism, human evidence, individual fit and the verification required before any protocol could be proposed.
For people asking whether MOTS-c is relevant to a defined objective, not looking for an unverified vial or an automatic protocol.Request a MOTS-c review →
Scientific dossier
The scientific page treats identity, target architecture, signalling, pharmacology, physiology, counterevidence and falsification independently from the service offer.
MOTS-c is a mitochondria-encoded 16-amino-acid peptide. MOTS-c is a mitochondrial-derived signalling peptide, not a generic mitochondrial supplement and not evidence that any administered formulation reproduces exercise biology.
The relevant causal architecture is cellular stress signalling, AMPK-linked metabolism and mitochondrial–nuclear communication. AMPK-linked cellular findings create a mechanistic hypothesis but do not establish mature human therapeutic efficacy, optimal route or dose.
A defensible discussion starts with the actual fatigue or metabolic phenotype, sleep, training load, energy intake, endocrine context, medication and objective baseline rather than the word ‘energy’.
Clinical relevance is only the first gate. A proposed route would also require a lawful pathway, current availability, exact formulation and presentation, responsible source, current lot, matching analytical documentation, receipt and storage controls. Clinic Terrain does not infer those facts from the molecule name or from a monograph.
The chosen endpoint may be glucose dynamics, exercise tolerance, recovery, fatigue burden or another predeclared measure; subjective stimulation alone is not enough. Continue, refine and stop decisions remain attached to the physician-reviewed record.
Direct answers
Yes. The clinical team can review the molecule, evidence and individual question. Assessment does not promise that a product is indicated, lawfully available, verified or supplied. MOTS-c access is considered only after the fatigue or metabolic question has a measurable baseline. Cellular AMPK biology is not used as a substitute for human dose, route and efficacy evidence.
No current product price is published for MOTS-c. A commercial quote would be inappropriate before the lawful route, exact presentation, current availability and matching product documentation are resolved.
AMPK-linked cellular findings create a mechanistic hypothesis but do not establish mature human therapeutic efficacy, optimal route or dose.
The chosen endpoint may be glucose dynamics, exercise tolerance, recovery, fatigue burden or another predeclared measure; subjective stimulation alone is not enough.
Evidence position
Sources used for this page
Primary sourceKumagai et al. Am J Physiol Endocrinol Metab. 2021. ↗MOTS-c is a 16-amino-acid peptide encoded within mitochondrial 12S rRNA.Primary sourceKim et al. MOTS-c translocates to the nucleus to regulate nuclear gene expression under metabolic stress. Cell Metab. 2018. ↗Experimental work connects MOTS-c with folate-cycle stress, de novo purine synthesis, AMPK activation, glucose utilisation and mitochondrial-to-nuclear signalling.Primary sourceRamanjaneya et al. Clin Endocrinol. 2019;91:278–287. ↗Human studies associate circulating MOTS-c with metabolic status, PCOS, insulin resistance, muscle biology and exercise.Regulatory guidanceWHO: good storage and distribution practices for medical products ↗This guidance defines supply-chain controls only. It does not prove the identity, purity, sterility or suitability of a specific product or lot.Primary sourceMOTS-c activates metabolic signalling but blunts reparative function in human mesenchymal stromal cells. Stem Cell Res Ther. 2026. ↗At the evidence cutoff, no adequate randomised human efficacy trial of native exogenous MOTS-c was identified.Regulatory guidanceICH: harmonised pharmaceutical quality guidelines ↗This framework explains what a quality system must establish. It is not analytical evidence for a Clinic Terrain product or lot.Your first message · Where you are + what you need help with